You might also like
Tandem Diabetes Care, Inc. (TNDM) is a medical device company specializing in the design, development, and commercialization of innovative technology solutions for diabetes management. The company primarily serves individuals with type 1 diabetes and is expanding its offerings to include those with type 2 diabetes requiring intensive insulin therapy. Tandem's product portfolio includes advanced insulin pumps, automated insulin delivery systems, and related consumables, all designed to improve glycemic control and enhance the quality of life for users.
- Supplies and Other - Provides disposable insulin cartridges, infusion sets, and other consumables used with Tandem's insulin pumps, ensuring recurring revenue and continuous support for users.
- Insulin Pumps - Designs and sells durable insulin pumps, including the flagship t:slim X2 and the Tandem Mobi, which integrate with continuous glucose monitoring (CGM) systems and feature advanced automated insulin delivery (AID) technology.
- t:slim X2 Insulin Pump - Offers remote software updates, CGM integration, and AID capabilities to optimize insulin delivery.
- Tandem Mobi Insulin Pump - The world’s smallest durable AID system, featuring mobile app control, inductive charging, and on-pump bolusing for enhanced discretion and flexibility.
- Control-IQ Technology - Provides an advanced hybrid-closed loop system that integrates with CGM sensors to automatically adjust insulin delivery and improve glycemic outcomes.
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
John Sheridan ExecutiveBoard | President, CEO, and Director | Director at Acutus Medical, Inc. | John Sheridan joined TNDM in April 2013 and became CEO in March 2019. He has led the company to record sales and product innovations. | View Report → |
Elizabeth Gasser Executive | Executive Vice President and Chief Strategy and Product Officer | N/A | Elizabeth Gasser joined TNDM in June 2021. She oversees strategy, corporate development, and product management, contributing to the company's growth and innovation. | |
James Leal Executive | Chief Manufacturing Officer | N/A | James Leal joined TNDM in October 2010. He has been instrumental in overseeing manufacturing and operations, contributing to the company's growth. | |
Jean-Claude Kyrillos Executive | Executive Vice President and Chief Operating Officer | Independent Board Director at San Diego Blood Bank | Jean-Claude Kyrillos joined TNDM in June 2024. He has deep experience in healthcare, previously holding leadership roles at Envista Holdings and Qualcomm Life. | |
Leigh Vosseller Executive | Executive Vice President, CFO, and Treasurer | Director at Girls Inc. of San Diego | Leigh Vosseller joined TNDM in 2013 and became CFO in June 2018. She has a strong background in finance and has held leadership roles at Genoptix and Biosite. | |
Mark Novara Executive | Executive Vice President and Chief Commercial Officer | N/A | Mark Novara joined TNDM in November 2023. He has extensive experience in medical devices and pharmaceuticals, previously working at McKinsey & Company and Becton Dickinson. | |
Rick Carpenter Executive | Chief Technical Officer | N/A | Rick Carpenter joined TNDM in November 2021. He oversees technical operations, leveraging his experience from Inseego Corporation and Capsule Technologies. | |
Shannon Hansen Executive | Executive Vice President, Chief Legal, Privacy & Compliance Officer, and Secretary | Independent External Audit and Supervisory Board Member at PHC Holdings Corporation | Shannon Hansen joined TNDM in January 2022. She oversees legal, compliance, and privacy functions, with previous roles at Alto Pharmacy and Abbott. | |
Susan Morrison Executive | Executive Vice President and Chief Administrative Officer | N/A | Susan Morrison joined TNDM in November 2007 and has held various leadership roles. She oversees investor relations, corporate communications, and human resources. | |
Christopher Twomey Board | Board Member | Chair of the Audit Committee at Bionano Genomics | Christopher Twomey has been a board member since July 2013. He has extensive experience in financial management and auditing, serving as Chair of the Audit Committee at Tandem and Bionano Genomics. | |
Dick Allen Board | Board Member | Involved with JDRF and Mary & Dick Allen Diabetes Center | Dick Allen has been a board member since July 2007. He has over 50 years of experience in healthcare and has been actively involved in the diabetes community. | |
Joao Malagueira Board | Board Member | President for three divisions at Hologic | Joao Malagueira joined the board in June 2022. He has over 25 years of experience in diabetes and medical devices, with a focus on global strategies. | |
Kathleen McGroddy-Goetz Board | Board Member | N/A | Kathleen McGroddy-Goetz joined the board in June 2020. She has over 25 years of experience in commercializing technologies in healthcare and life sciences. | |
Myoungil Cha Board | Board Member | Chief Product Officer at Verily | Myoungil Cha joined the board in June 2022. He has extensive experience in healthcare and consumer technology, previously working at Carbon Health and Apple. | |
Peyton Howell Board | Board Member | CEO and Board Member at Parexel International; Chairperson of ACRO | Peyton Howell joined the board in August 2020. She has over 30 years of experience in healthcare, with expertise in reimbursement and patient access. | |
Rebecca Robertson Board | Chair of the Board of Directors | Founder and General Partner at Versant Ventures | Rebecca Robertson has been a board member since January 2019 and Chair since March 2023. She provides strategic direction with her extensive experience in medical technology. |
- Given the potential for tariffs affecting components sourced from Asia, how are you mitigating supply chain risks, and what specific contingency plans do you have to address possible cost increases or disruptions?
- With new pump introductions previously causing market pauses, what strategies are you implementing to ensure that your latest products accelerate adoption without further disrupting market growth?
- As competitors offer type 2 diabetes indications and given the underpenetrated insulin-intensive type 2 market, how do you plan to capture significant market share upon FDA approval, and what impact do you expect this to have on your growth in the next few years?
- Can you provide more clarity on how transitioning to the pharmacy channel will affect your pricing and margins, especially in comparison to competitors who price at a premium in this channel?
- Considering the gross margin pressures from the Mobi launch, how confident are you in meeting your 2025 margin objectives, and what specific measures are you taking to ensure Mobi becomes accretive to margins as anticipated?
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
A major competitor in the insulin delivery device market, which includes insulin pumps and related technologies. The company is noted for its market acceptance and competitive pricing strategies. | |
A leading competitor in the medical device industry, particularly in insulin delivery systems. The company benefits from established relationships with healthcare providers and a strong reputation in the diabetes industry. | |
Ypsomed | A competitor in the insulin delivery device market, focusing on insulin pumps and related software applications. |
A collaborator and competitor in the continuous glucose monitoring (CGM) space, providing technology that integrates with insulin pump products. | |
A competitor in the glucose sensor market, offering products that compete with Dexcom CGMs and collaborating on integrated diabetes solutions. | |
Roche Diabetes Care | A competitor involved in patent litigation with Tandem Diabetes Care, alleging infringement related to insulin pump technology. |
| Customer | Relationship | Segment | Details |
|---|---|---|---|
Distributor A | Independent distributor | All | 2024: ~$105.3M (11.2%) of total revenue [0][1][3], ~$12.1M (11.1%) of AR [2][3]. Also 12.2% of revenue in 2023 and 11.6% in 2022 [6]. |
Distributor B | Independent distributor | All | 2023: 10.5% of AR [6]. (Less than 10% in 2024 [3].) |
Distributor C | Independent distributor | All | 2024: 11.8% of AR (~$13.5M) [2][3]; less than 10% of revenue [3]. |
Distributor D | Independent distributor | All | 2024: ~$108.1M (11.5%) of total revenue [0][1][3], ~$12.4M (11.2%) of AR [2][3]. Also 10.8% of revenue in 2023 and 14.4% in 2022 [6]. |
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
AMF Medical SA | 2023 | Tandem Diabetes Care's acquisition of AMF Medical SA was completed on January 19, 2023, involving a strategic investment of CHF 8.0 million, a CHF 62.4 million cash payment at closing, and additional contingent earnout payments up to CHF 129.6 million; the deal was structured as an asset acquisition with a $78.8 million charge for IPR&D assets. This move adds the Swiss developer's patch pump technology to Tandem’s portfolio, aligning with their strategic vision to expand into ergonomic, rechargeable patch pump solutions. |
Capillary Biomedical, Inc. | 2022 | Completed on July 21, 2022, this acquisition involved a total cash consideration of $24.7 million, the assumption of $4.7 million in long-term debt, and a $31.0 million charge recorded for IPR&D assets; the transaction was structured as an asset acquisition. It strategically brings in Capillary's extended-wear infusion set technology to further Tandem’s innovation in infusion set solutions, enhancing product development aimed at extended wear and improved user experience. |
Recent developments and announcements about TNDM.
Earnings
New Earnings (Q4 2024)
·Mar 7, 2025, 1:22 AMView full earnings summary →TNDM’s T2 clearance could double its addressable market. They plan to boost T2 share from 5% to 25%+ in 3.5 years, aided by 20% pharmacy coverage and a nearly complete salesforce expansion. Despite a muted Q4, these moves suggest strong multiyear growth.